Walmart Inc. Common Stock WMT

The Motley Fool 13 nov

As AI data center power demand is projected to double by 2030, both Bloom Energy (on-site fuel cells) and Constellation Energy (nuclear grid power) are positioned to benefit. Bloom offers faster deployment with 55-day installations and expanded partnerships with Oracle and Brookfield, while Constellation leverages its massive nuclear fleet and long-term power purchase agreements with major tech companies. Analysts view Bloom as higher upside short-term and Constellation as better long-term value.

The Motley Fool 12 nov

The article compares e.l.f. Beauty and lululemon athletica as investment options for 2027. e.l.f. Beauty is highlighted as a high-growth cosmetics disruptor with 24.6% revenue growth and 31 consecutive quarters of sales increases, though it carries a high P/E ratio of 82.65. Lululemon athletica is presented as a more established, profitable player with a 14.2% net margin and lower valuation (P/E of 8.81), but faces slower 4.9% growth and business pressures. The analyst recommends e.l.f. Beauty for its sustained growth momentum despite higher valuation.

Zacks Investment Research 12 nov

Walmart is expected to report Q3 2026 earnings of $0.64 per share (up 3.2% YoY) and revenues of $186.52 billion (up 3.9% YoY) on November 19. With a positive Earnings ESP of +0.74% and Zacks Rank #3, the company appears positioned to beat consensus estimates. Walmart has beaten EPS estimates in all four of the last quarters, including a +10.96% surprise in the most recent quarter.

Zacks Investment Research 12 nov

Walmart (WMT) is highlighted as a stock to watch with a Zacks Rank #3 (Hold) rating and a VGM Score of B. The company has shown strong momentum with shares up 8.2% over the past four weeks. Three analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $2.88 per share for fiscal 2027. The stock boasts an average earnings surprise of +3.9%.

Zacks Investment Research 12 nov

Zacks equity research analysts published analysis on five stocks. NVIDIA faces China restrictions and competition but benefits from AI infrastructure demand. Walmart outperforms its industry with strong omnichannel operations but faces cost pressures. AbbVie offsets Humira's decline with strong growth from newer drugs. Pioneer Bancorp outperforms its industry with solid fundamentals. Aspira significantly underperforms its industry with liquidity constraints and execution risks.